FDA approves fixed dose atazanavir/cobicistat
BMS press release
On 29 January 2015, the FDA approved the fixed dose of the protease inhibitor atazanavir 300 mg with the PK booster (CP3A4 inhibitor) cobicistat 150 mg.
The indication is to treat HIV-1 in combination with other ARVs for treatment-naive and -experienced adults.
The brand name for the combination is Evotaz. Atazanavir is marketed by Bristol-Myers Squibb who led this collaboration and cobicistat by Gilead.
BMS PR. U.S. Food and Drug Administration approves Bristol-Myers Squibb’s Evotaz (atazanavir and cobicistat) for the treatment of HIV-1 infection in adults. (29 January 2015).